November 28, 2019
Ono Pharmaceutical said on November 27 that it has filed its approval-pending BTK inhibitor tirabrutinib for two additional indications in Japan for the treatment of patients with Waldenstrom macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL). The submission is based on data...read more